| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/26/2011 | US7932290 Method for the treatment of metabolic disorders |
| 04/26/2011 | US7932289 Remedy for diabetes |
| 04/26/2011 | US7932288 Composition for relieving subjective symptoms of fatigue |
| 04/26/2011 | US7932287 Therapeutic compositions and uses |
| 04/26/2011 | US7932286 Method for treating colonic viscerosensitivity and spasticity |
| 04/26/2011 | US7932285 Compounds from Antrodia camphorata |
| 04/26/2011 | US7932284 Indole sulfonamide modulators of progesterone receptors |
| 04/26/2011 | US7932282 Imidazolidine carboxamide derivatives as P2X7 modulators |
| 04/26/2011 | US7932281 Amine-based compound and use thereof |
| 04/26/2011 | US7932280 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 04/26/2011 | US7932279 Substituted tetrazole compounds and uses thereof |
| 04/26/2011 | US7932278 2-aminoethoxyacetic acid derivatives and their use |
| 04/26/2011 | US7932277 Peptide inhibitors of hepatitis C virus replication |
| 04/26/2011 | US7932276 administering a thiazole compounds with reduce side effect; 6-[2-(3,4-diethoxyphenyl)-thiazol-4-yl]pyridine-2-carboxylic acid |
| 04/26/2011 | US7932274 3-indazolyl-4-pyridylisothiazoles |
| 04/26/2011 | US7932273 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
| 04/26/2011 | US7932272 Antifungal agent containing heterocyclic compound |
| 04/26/2011 | US7932271 Heterocyclic methyl sulfone derivative |
| 04/26/2011 | US7932270 Certain chemical entities, compositions, and methods |
| 04/26/2011 | US7932269 Sulfonamides as orexin antagonists |
| 04/26/2011 | US7932268 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| 04/26/2011 | US7932267 Use of α-glucosidase inhibitors to treat alphavirus infections |
| 04/26/2011 | US7932266 Ester or amide derived from (3-sec-butyl-1-(thio)oxo-2,3-dihydro-1H-isoquinolin-4-yliden)-acetic acid; neurodegenerative diseases, cerebral and cardiac ischemias |
| 04/26/2011 | US7932265 Solution formulations of sirolimus and its analogs for CAD treatment |
| 04/26/2011 | US7932264 Sinomenine derivatives and preparation and uses thereof |
| 04/26/2011 | US7932263 Therapeutic treatment |
| 04/26/2011 | US7932262 Quinazolines for PDK1 inhibition |
| 04/26/2011 | US7932261 Macrocycle derivatives useful as inhibitors of β-secretase (BACE) |
| 04/26/2011 | US7932260 5-methyl-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 3-(4-fluoro-phenyl)-5-methyl-2-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ethyl]-3H-quinazolin-4-one; bone-resorption disorder or a cancer of a hematopoietic origin; disorders in which PI3K plays a role in leukocyte function |
| 04/26/2011 | US7932259 Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group |
| 04/26/2011 | US7932258 Pharmaceutical form having an active substance-containing core which is coated with the partially neutralized, anionic (meth)acrylate copolymer and releases at least 30% of the contained active substance in 30 minutes at a pH at which the active substance is adequately soluble and stable; drug delivery |
| 04/26/2011 | US7932257 Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
| 04/26/2011 | US7932256 (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
| 04/26/2011 | US7932255 Controlling cell proliferation |
| 04/26/2011 | US7932254 Pyrrolopyrazine kinase inhibitors |
| 04/26/2011 | US7932253 Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors |
| 04/26/2011 | US7932252 CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds |
| 04/26/2011 | US7932251 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| 04/26/2011 | US7932250 Thienopyrazole derivative having PDE7 inhibitory activity |
| 04/26/2011 | US7932249 Olanzapine pamoate dihydrate |
| 04/26/2011 | US7932248 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity |
| 04/26/2011 | US7932247 M3 muscarinic acetylcholine receptor antagonists |
| 04/26/2011 | US7932246 Histone deacetylase inhibitors |
| 04/26/2011 | US7932245 Spirocyclopropyl amides and acids and their therapeutic applications |
| 04/26/2011 | US7932244 Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| 04/26/2011 | US7932243 Bile preparations for gastrointestinal disorders |
| 04/26/2011 | US7932242 Anticancer agents; radiation and chemical resistance |
| 04/26/2011 | US7932241 Filling plastic container with bisphosphonate solution; heat sterilization |
| 04/26/2011 | US7932240 Phosphadiazine HCV polymerase inhibitors IV |
| 04/26/2011 | US7932239 Methods of and compositions for reducing neuronal cell death |
| 04/26/2011 | US7932238 reducing sugar content of less than 20%, and number-average molecular mass Mn at most equal to 4500 g/mol; total fiber content greater than 50% on a dry matter basis; with other active ingredients such as sulfasalazines, corticoids, and anti-inflammatory agent for the bowel |
| 04/26/2011 | US7932237 Pharmaceutical compositions for use in the treatment of wounds |
| 04/26/2011 | US7932236 Glycolipids |
| 04/26/2011 | US7932235 Triazolyl tropane derivatives |
| 04/26/2011 | US7932234 Bispecific oligonucleotide for the treatment of CNS malignancies |
| 04/26/2011 | US7932233 Fungal phytotoxin fusicoccin for the treatment and diagnosis of coagulation-correlated pathologies |
| 04/26/2011 | US7932232 Cosmetic composition comprising beta-fructosyl-L-ascorbic acid for skin whitening |
| 04/26/2011 | US7932230 Antifungal paints and coatings |
| 04/26/2011 | US7932229 Peptides for treatment of tumors/cancer |
| 04/26/2011 | US7932026 EGFR mutations |
| 04/26/2011 | US7931917 Phospholipid-free, having a D50 particle size of less than 500 nm, and having a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability |
| 04/26/2011 | US7931915 Extended release venlafaxine formulation |
| 04/26/2011 | US7931022 Method and apparatus for dispensing inhalator medicament |
| 04/26/2011 | CA2634676C Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp |
| 04/26/2011 | CA2623639C Agent for improving insulin resistance |
| 04/26/2011 | CA2616544C Agent for improving insulin resistance |
| 04/26/2011 | CA2615418C A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it |
| 04/26/2011 | CA2612286C Substituted arylpyrazoles as parasiticidal agents |
| 04/26/2011 | CA2601458C Benzimidazolone derivatives as cb2 receptor ligands |
| 04/26/2011 | CA2584060C Use of agomelatin to produce medications for treating generalized anxiety disorder |
| 04/26/2011 | CA2562581C Electronic atomization cigarette |
| 04/26/2011 | CA2546970C Imidazole derivatives, processes for preparing them and their uses |
| 04/26/2011 | CA2543676C Tyrosinase activity inhibitor and ameliorant for facial blood flow |
| 04/26/2011 | CA2543350C Disintegratable films for diagnostic devices |
| 04/26/2011 | CA2529538C Pyridoxamine for the treatment of diabetic kidney disease |
| 04/26/2011 | CA2522577C Hepatitis c inhibitor compounds |
| 04/26/2011 | CA2519410C Pharmaceutical composition and procedure to treat and prevent prostatic hyperplasia and prostatitis from the royal palm (roystonea regia) fruits |
| 04/26/2011 | CA2517930C Pyridylsulfonamido pyrimidines for treating diabetic nephropathy |
| 04/26/2011 | CA2508474C Pesticidal sulphonylaminopyrazoles |
| 04/26/2011 | CA2504873C Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one |
| 04/26/2011 | CA2500952C Neurologically-active compounds |
| 04/26/2011 | CA2496611C Agent delivery particle |
| 04/26/2011 | CA2495879C Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders |
| 04/26/2011 | CA2491506C N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 04/26/2011 | CA2483067C Method of forming iron hydroxypyrone compounds |
| 04/26/2011 | CA2479133C 2-4-diaminopyrimidine derivatives |
| 04/26/2011 | CA2477657C Cathepsin cysteine protease inhibitors |
| 04/26/2011 | CA2471059C Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 04/26/2011 | CA2468038C Preparation of trans-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives |
| 04/26/2011 | CA2467718C Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 04/26/2011 | CA2465103C Use of a prostaglandin derivative as an anti-pruritic agent |
| 04/26/2011 | CA2462657C Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| 04/26/2011 | CA2462416C Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 04/26/2011 | CA2460145C Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 04/26/2011 | CA2447999C Caspase inhibitors and uses thereof |
| 04/26/2011 | CA2446619C Permeation enhancers |
| 04/26/2011 | CA2446461C Substituted cyclohexane-1,4-diamine derivatives |
| 04/26/2011 | CA2439480C Carbamate compounds for use in preventing or treating psychotic disorders |
| 04/26/2011 | CA2439337C Highly sulfated derivatives of k5 polysaccharide and their preparation |
| 04/26/2011 | CA2438713C Dibenzo[c]chromen-6-one derivatives as anti-cancer agents |